-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ETX-101 in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ETX-101 in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ETX-101 in Dravet Syndrome (Severe Myoclonic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vesleteplirsen in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vesleteplirsen in Duchenne Muscular Dystrophy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vesleteplirsen in Duchenne Muscular Dystrophy Drug Details: Vesleteplirsen is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zorevunersen Sodium in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zorevunersen Sodium in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zorevunersen Sodium in Dravet Syndrome...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tenecteplase in Acute Ischemic Stroke
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tenecteplase in Acute Ischemic Stroke report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tenecteplase in Acute Ischemic Stroke Drug Details: Tenecteplase (Metalyse, Tnkase)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tenecteplase in Acute Respiratory Failure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tenecteplase in Acute Respiratory Failure report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tenecteplase in Acute Respiratory Failure Drug Details: Tenecteplase (Metalyse, Tnkase)...
-
Sector Analysis
NewCAD/CAM Systems and Materials Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
CAD/CAM Systems and Materials Market Report Overview The CAD/CAM systems and materials market size was valued at $3.93 billion in 2023 and is expected to grow at a CAGR of more than 5% during the forecast period 2023 and 2033. CAD/CAM materials are used to fabricate temporary and permanent dental restorations on a CAD/CAM system. CAD/CAM Systems and Materials Market Outlook 2023-2023 ($ Billion) Buy the Full Report for More Insights on the CAD/CAM Systems and Materials Market Forecast, Download...
-
Product Insights
NewXeltis AG Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Xeltis AG Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Xeltis AG (Xeltis) is a clinical-stage medical equipment company that harnesses advances in science to improve the treatment of heart valve related conditions. Its polymer-based technology platform, RestoreX, facilitates the natural restoration of heart valve through a process referred to as endogenous tissue restoration (ETR). Based on supramolecular chemistry, the company develops bioabsorbable synthetic heart valves and vascular grafts to...
-
Company Insights
NewEfemoral Medical LLC Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our Efemoral Medical LLC Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. Efemoral Medical LLC is a medical technology company focused on developing devices that restore flow in blood vessels. The company is headquartered in United States. GlobalData's Medical Devices company profile report, “Efemoral Medical LLC Pipeline Insight and Competitive Landscape, 2024" provides information about the company overview and analysis on their pipeline products. This company profile report provides key information...
-
Sector Analysis
NewDental Handpieces Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
Dental Handpieces Market Report Overview The dental handpieces market size was $834.5 million in 2023. The market will grow at a CAGR of more than 2% during 2023-2033. Dental handpieces are instruments for holding dental burs to remove tooth structure or to smooth and polish restorative materials. Dental Handpieces Market Outlook 2023-2033 ($ Million) Buy the Full Report for More Insights on the Dental Handpieces Market Forecast, Download a Free Sample Report The dental handpieces market research report identifies quantitative...